Evidence map›Paper›PMID 38140550›Full record

ArticleViruses2023

COVID-19 Genomic Surveillance in Bangui (Central African Republic) Reveals a Landscape of Circulating Variants Linked to Validated Antiviral Targets of SARS-CoV-2 Proteome.

Ulrich Vickos, Marianna Camasta, Nicole Grandi, Sante Scognamiglio, Tobias Schindler, Marie Roseline Darnycka Belizaire, Ernest Lango-Yaya, Giscard Wilfried Koyaweda, Oscar Senzongo, Simon Pounguinza and 9 more

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 5 countries.

Ulrich VickosDepartment of Diagnostic and Laboratory Medicine, UOC Microbiology and Immunology Diagnostics, Children's Hospital Bambino Gesù, IRCCS, 00118 Rome, Italy.ORCID 0000-0001-5877-9836
Marianna CamastaLaboratory of Molecular Virology, Department of Life and Environmental Sciences, University of Cagliari, 09042 Monserrato, Italy.ORCID 0009-0006-3516-9844
Nicole GrandiLaboratory of Molecular Virology, Department of Life and Environmental Sciences, University of Cagliari, 09042 Monserrato, Italy.
Sante ScognamiglioLaboratory of Molecular Virology, Department of Life and Environmental Sciences, University of Cagliari, 09042 Monserrato, Italy.ORCID 0000-0003-3076-1823
Tobias SchindlerSwiss Tropical and Public Health Institute, 4123 Allschwil, Switzerland.
Marie Roseline Darnycka BelizaireCentral African Republic Office, World Health Organization (WHO) Representation, Bangui 94045, Central African Republic.ORCID 0000-0003-3771-7841
Ernest Lango-YayaClinical Biology and Public Health National Laboratory, Bangui 94045, Central African Republic.
Giscard Wilfried KoyawedaClinical Biology and Public Health National Laboratory, Bangui 94045, Central African Republic.
Oscar SenzongoClinical Biology and Public Health National Laboratory, Bangui 94045, Central African Republic.
Simon PounguinzaClinical Biology and Public Health National Laboratory, Bangui 94045, Central African Republic.
Kaleb Kandou Jephté Francis EstiméClinical Biology and Public Health National Laboratory, Bangui 94045, Central African Republic.
Stephanie N'yetoboukoClinical Biology and Public Health National Laboratory, Bangui 94045, Central African Republic.
Christelle Luce Bobossi GadiaClinical Biology and Public Health National Laboratory, Bangui 94045, Central African Republic.
Dominos-Alfred FeiganazouiClinical Biology and Public Health National Laboratory, Bangui 94045, Central African Republic.
Alain Le FaouEA 3452 CITHEFOR, Campus Brabois Santé, 54500 Vandœuvre-lès-Nancy, France.
Massimiliano OrsiniGeneral and Experimental Microbiology, Laboratory of Microbial Ecology and Genomics of Microorganisms, Experimental Zooprophylactic Institute of the Venezie (IZSVe), 35020 Legnaro, Italy.
Carlo Federico PernoDepartment of Diagnostic and Laboratory Medicine, UOC Microbiology and Immunology Diagnostics, Children's Hospital Bambino Gesù, IRCCS, 00118 Rome, Italy.
Luca ZinzulaDepartment of Structural Molecular Biology, Max Planck Institute of Biochemistry, 82152 Martinsried, Germany.ORCID 0000-0001-6489-7070
Clotaire Donatien RafaïClinical Biology and Public Health National Laboratory, Bangui 94045, Central African Republic.
University of Bangui · CFUniversity of Cagliari · ITBambino Gesù Children's Hospital · ITCibles thérapeutiques, formulation et expertise préclinique du médicamentIstituto Zooprofilattico Sperimentale delle Venezie · ITMax Planck Institute of Biochemistry · DESwiss Tropical and Public Health Institute · CH

Funding

World Health Organization 001
6 · The paper itself

Abstract

Since its outbreak, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spread rapidly, causing the Coronavirus Disease 19 (COVID-19) pandemic. Even with the vaccines' administration, the virus continued to circulate due to inequal access to prevention and therapeutic measures in African countries. Information about COVID-19 in Africa has been limited and contradictory, and thus regional studies are important. On this premise, we conducted a genomic surveillance study about COVID-19 lineages circulating in Bangui, Central African Republic (CAR). We collected 2687 nasopharyngeal samples at four checkpoints in Bangui from 2 to 22 July 2021. Fifty-three samples tested positive for SARS-CoV-2, and viral genomes were sequenced to look for the presence of different viral strains. We performed phylogenetic analysis and described the lineage landscape of SARS-CoV-2 circulating in the CAR along 15 months of pandemics and in Africa during the study period, finding the Delta variant as the predominant Variant of Concern (VoC). The deduced aminoacidic sequences of structural and non-structural genes were determined and compared to reference and reported isolates from Africa. Despite the limited number of positive samples obtained, this study provides valuable information about COVID-19 evolution at the regional level and allows for a better understanding of SARS-CoV-2 circulation in the CAR.

Indexed as

COVID-19SARS-CoV-2Antiviral AgentsCentral African RepublicGenomicsHumansPhylogenyProteomeAntiviral AgentsProteomeCentral African RepublicCOVID-19Delta variantSARS-CoV-2screeningsevere acute respiratory syndrome coronavirus 2

Identifiers

PMID38140550
PMCPMC10748234
OpenAlexW4388977874

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.